Effect of duloxetine on pain , function , and quality of life among <font color="blue">patients_3</font> <font color="blue">with_3</font> <font color="blue">chemotherapy_4</font> <font color="blue">-_4</font> <font color="blue">induced_4</font> <font color="blue">painful_4</font> <font color="blue">peripheral_4</font> <font color="blue">neuropathy_4</font> <font color="blue">:_4</font> a randomized clinical trial . 
<br>
<br> IMPORTANCE There are no known effective treatments for <font color="blue">painful_1</font> <font color="blue">chemotherapy_1</font> <font color="blue">-_1</font> <font color="blue">induced_1</font> <font color="blue">peripheral_1</font> <font color="blue">neuropathy_1</font> <font color="blue">._1</font> 
<br> OBJECTIVE To determine the effect of duloxetine , 60 mg daily , on average pain severity . 
<br> DESIGN , SETTING , AND PATIENTS Randomized , double - blind , placebo - controlled crossover trial at <font color="blue">8_2</font> <font color="blue">National_2</font> <font color="blue">Cancer_2</font> <font color="blue">Institute_2</font> <font color="blue">(_2</font> <font color="blue">NCI)-funded_2</font> <font color="blue">cooperative_2</font> <font color="blue">research_2</font> <font color="blue">networks_2</font> <font color="blue">that_2</font> <font color="blue">enrolled_2</font> <font color="blue">231_7</font> <font color="blue">patients_7</font> <font color="blue">who_7</font> <font color="blue">were_7</font> <font color="blue">25_7</font> <font color="blue">years_7</font> <font color="blue">or_7</font> <font color="blue">older_7</font> <font color="blue">being_7</font> <font color="blue">treated_7</font> <font color="blue">at_7</font> <font color="blue">community_7</font> <font color="blue">and_7</font> <font color="blue">academic_7</font> <font color="blue">settings_7</font> <font color="blue">between_6</font> <font color="blue">April_6</font> <font color="blue">2008_6</font> <font color="blue">and_6</font> <font color="blue">March_6</font> <font color="blue">2011_6</font> <font color="blue">._6</font> Study follow - up was completed July 2012 . <font color="blue">Stratified_1</font> <font color="blue">by_1</font> <font color="blue">chemotherapeutic_1</font> <font color="blue">drug_1</font> <font color="blue">and_1</font> <font color="blue">comorbid_1</font> <font color="blue">pain_1</font> <font color="blue">risk_1</font> <font color="blue">,_1</font> patients were randomized to receive either duloxetine followed by placebo or placebo followed by duloxetine . <font color="blue">Eligibility_3</font> <font color="blue">required_3</font> <font color="blue">that_3</font> <font color="blue">patients_5</font> <font color="blue">have_5</font> <font color="blue">grade_5</font> <font color="blue">1_5</font> <font color="blue">or_5</font> <font color="blue">higher_5</font> <font color="blue">sensory_5</font> <font color="blue">neuropathy_5</font> <font color="blue">according_5</font> <font color="blue">to_5</font> <font color="blue">the_5</font> <font color="blue">NCI_5</font> <font color="blue">Common_5</font> <font color="blue">Terminology_5</font> <font color="blue">Criteria_5</font> <font color="blue">for_5</font> <font color="blue">Adverse_5</font> <font color="blue">Events_5</font> <font color="blue">and_5</font> <font color="blue">at_5</font> <font color="blue">least_5</font> <font color="blue">4_5</font> <font color="blue">on_5</font> <font color="blue">a_5</font> <font color="blue">scale_5</font> <font color="blue">of_5</font> <font color="blue">0_5</font> <font color="blue">to_5</font> <font color="blue">10_5</font> <font color="blue">,_5</font> <font color="blue">representing_5</font> <font color="blue">average_5</font> <font color="blue">chemotherapy_5</font> <font color="blue">-_5</font> <font color="blue">induced_5</font> <font color="blue">pain_5</font> <font color="blue">,_5</font> <font color="blue">after_5</font> <font color="blue">paclitaxel_5</font> <font color="blue">,_5</font> <font color="blue">other_5</font> <font color="blue">taxane_5</font> <font color="blue">,_5</font> <font color="blue">or_5</font> <font color="blue">oxaliplatin_5</font> <font color="blue">treatment_5</font> <font color="blue">._5</font> <font color="blue">
<br>_2</font> INTERVENTIONS The initial treatment consisted of taking 1 capsule daily of either 30 mg of duloxetine or placebo for the first week and 2 capsules of either 30 mg of duloxetine or placebo daily for 4 additional weeks . 
<br> MAIN OUTCOME MEASURES The primary hypothesis was that duloxetine would be more effective than placebo in decreasing <font color="blue">chemotherapy_1</font> <font color="blue">-_1</font> <font color="blue">induced_1</font> <font color="blue">peripheral_1</font> <font color="blue">neuropathic_1</font> <font color="blue">pain_1</font> <font color="blue">._1</font> Pain severity was assessed using the Brief Pain Inventory - Short Form " average pain " item with 0 representing no pain and 10 representing as bad as can be imagined . 
<br> RESULTS Individuals receiving duloxetine as their initial 5-week treatment reported a mean decrease in average pain of 1.06 ( 95% CI , 0.72 - 1.40 ) vs 0.34 ( 95% CI , 0.01 - 0.66 ) among those who received placebo ( P = .003 ; effect size , 0.513 ) . The observed mean difference in the average pain score between duloxetine and placebo was 0.73 ( 95% CI , 0.26 - 1.20 ) . Fifty - nine percent of those initially receiving duloxetine vs 38% of those initially receiving placebo reported decreased pain of any amount . 
<br> CONCLUSION AND RELEVANCE Among <font color="blue">patients_1</font> <font color="blue">with_1</font> <font color="blue">painful_1</font> <font color="blue">chemotherapy_1</font> <font color="blue">-_1</font> <font color="blue">induced_1</font> <font color="blue">peripheral_1</font> <font color="blue">neuropathy_1</font> <font color="blue">,_1</font> the use of duloxetine compared with placebo for 5 weeks resulted in a greater reduction in pain . 
<br> TRIAL REGISTRATION clinicaltrials.gov Identifier : NCT00489411 .